NI201400002A - N - ( 6 - (( 2r, 3s) - 3, 4 - dihidroxibutan - 2 - iloxi) - 2 - ( 4 - fluorobenciltio ) pirimidin - 4 - il ) - 3 - metilacetidina - 1 - sulfonamida como modulador del receptor de quimiocina - Google Patents

N - ( 6 - (( 2r, 3s) - 3, 4 - dihidroxibutan - 2 - iloxi) - 2 - ( 4 - fluorobenciltio ) pirimidin - 4 - il ) - 3 - metilacetidina - 1 - sulfonamida como modulador del receptor de quimiocina

Info

Publication number
NI201400002A
NI201400002A NI201400002A NI201400002A NI201400002A NI 201400002 A NI201400002 A NI 201400002A NI 201400002 A NI201400002 A NI 201400002A NI 201400002 A NI201400002 A NI 201400002A NI 201400002 A NI201400002 A NI 201400002A
Authority
NI
Nicaragua
Prior art keywords
compound
sulfonamide
methylacetidine
fluorobenzylthium
dihydroxibutan
Prior art date
Application number
NI201400002A
Other languages
English (en)
Inventor
Connolly Stephen
Richard Ebden Mark
Langer Thomas
Robert Steven Alan
Robert Stewart Craig
Margaret Tomlin Paula
Alastair Stewart Walters Iain
John Williams Andrew
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201400002A publication Critical patent/NI201400002A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms

Abstract

Se proporciona un compuesto que es (a) una sulfonamida pirimidina de fórmula (I) o (b) una sal farmacéuticamente aceptable de esta, formas cristalinas del compuesto, procesos para obtener el compuesto, intermediarios farmacéuticos utilizados en la fabricación del compuesto y composiciones farmacéuticas que contienen el compuesto. El compuesto es útil en el tratamiento de una enfermedad/trastorno en donde la modulación de la actividad del receptor de quimiocina es beneficiosa.
NI201400002A 2011-07-12 2014-01-09 N - ( 6 - (( 2r, 3s) - 3, 4 - dihidroxibutan - 2 - iloxi) - 2 - ( 4 - fluorobenciltio ) pirimidin - 4 - il ) - 3 - metilacetidina - 1 - sulfonamida como modulador del receptor de quimiocina NI201400002A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506737P 2011-07-12 2011-07-12

Publications (1)

Publication Number Publication Date
NI201400002A true NI201400002A (es) 2016-02-16

Family

ID=46513787

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400002A NI201400002A (es) 2011-07-12 2014-01-09 N - ( 6 - (( 2r, 3s) - 3, 4 - dihidroxibutan - 2 - iloxi) - 2 - ( 4 - fluorobenciltio ) pirimidin - 4 - il ) - 3 - metilacetidina - 1 - sulfonamida como modulador del receptor de quimiocina

Country Status (37)

Country Link
US (3) US8735413B2 (es)
EP (2) EP3255043B1 (es)
JP (2) JP6006308B2 (es)
KR (1) KR101946664B1 (es)
CN (1) CN103781781B (es)
AR (2) AR087168A1 (es)
AU (2) AU2012282316B2 (es)
BR (1) BR112014000636B1 (es)
CA (1) CA2841859C (es)
CL (1) CL2014000079A1 (es)
CO (1) CO6852072A2 (es)
CR (1) CR20140007A (es)
CU (2) CU24292B1 (es)
CY (1) CY1124329T1 (es)
DK (1) DK3255043T3 (es)
DO (1) DOP2013000308A (es)
EA (1) EA027821B1 (es)
EC (1) ECSP14013130A (es)
ES (1) ES2861927T3 (es)
HK (1) HK1245779A1 (es)
HR (1) HRP20210413T1 (es)
HU (1) HUE053703T2 (es)
IL (1) IL230398A (es)
LT (1) LT3255043T (es)
MX (2) MX342874B (es)
MY (1) MY180039A (es)
NI (1) NI201400002A (es)
PE (2) PE20181069A1 (es)
PL (1) PL3255043T3 (es)
PT (1) PT3255043T (es)
RS (1) RS61608B1 (es)
SG (1) SG10201605619XA (es)
SI (1) SI3255043T1 (es)
TW (2) TWI659026B (es)
UY (1) UY34191A (es)
WO (1) WO2013008002A1 (es)
ZA (1) ZA201401059B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2593448A1 (en) 2010-07-13 2013-05-22 AstraZeneca AB New cristalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3- dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MX342874B (es) * 2011-07-12 2016-10-17 Astrazeneca Ab N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.
EP2740458B1 (en) * 2012-12-06 2016-08-03 IP Gesellschaft für Management mbH Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
BR112018068393A2 (pt) * 2016-03-11 2019-01-15 Ardea Biosciences Inc inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais
EP3681861A4 (en) * 2017-09-12 2021-06-09 Ardea Biosciences, Inc. CXCR-2 INHIBITORS FOR THE TREATMENT OF DISORDERS
JP7355858B2 (ja) * 2019-06-12 2023-10-03 ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ 水性側流からカルボン酸を単離するための方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3457278A (en) * 1964-10-15 1969-07-22 Geigy Chem Corp Cyclopropyl-4-sulfanilamido-pyrimidines
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
FI981521A0 (fi) * 1998-07-01 1998-07-01 Orion Corp Substituoidut beta-diketonit ja niiden käyttö
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
GB0419235D0 (en) * 2004-08-28 2004-09-29 Astrazeneca Ab Compounds
EP2311827A1 (en) * 2004-08-28 2011-04-20 AstraZeneca AB Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.
CA2637631C (en) * 2006-01-19 2014-04-29 Orchid Research Laboratories Limited Pyrimidine compounds and uses thereof
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
CN102159555A (zh) * 2008-07-16 2011-08-17 阿斯利康(瑞典)有限公司 嘧啶基氨磺酰衍生物及其治疗趋化因子介导的疾病的用途
CN102105434A (zh) 2008-07-25 2011-06-22 巴斯夫欧洲公司 3-氨基甲基-1-环己基胺及其生产方法
EP2593448A1 (en) * 2010-07-13 2013-05-22 AstraZeneca AB New cristalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3- dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MX342874B (es) * 2011-07-12 2016-10-17 Astrazeneca Ab N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.

Also Published As

Publication number Publication date
EA201490077A1 (ru) 2014-10-30
US20140228339A1 (en) 2014-08-14
KR101946664B1 (ko) 2019-02-11
US9221782B2 (en) 2015-12-29
PT3255043T (pt) 2021-03-29
BR112014000636A2 (pt) 2017-01-10
LT3255043T (lt) 2021-04-12
JP6261666B2 (ja) 2018-01-17
US20160108023A1 (en) 2016-04-21
WO2013008002A1 (en) 2013-01-17
CU24292B1 (es) 2017-12-08
EP3255043A3 (en) 2018-04-18
HRP20210413T1 (hr) 2021-05-14
AU2016244246B2 (en) 2017-11-23
CN103781781B (zh) 2015-08-26
CR20140007A (es) 2014-05-14
NZ619001A (en) 2016-05-27
CO6852072A2 (es) 2014-01-30
JP2014520838A (ja) 2014-08-25
CL2014000079A1 (es) 2014-06-27
KR20140037915A (ko) 2014-03-27
US8735413B2 (en) 2014-05-27
AR124688A2 (es) 2023-04-26
TWI659026B (zh) 2019-05-11
EP2731945A1 (en) 2014-05-21
SG10201605619XA (en) 2016-08-30
CA2841859C (en) 2021-03-09
MY180039A (en) 2020-11-20
DOP2013000308A (es) 2014-02-28
UY34191A (es) 2013-02-28
EP3255043A2 (en) 2017-12-13
ECSP14013130A (es) 2014-02-28
CU20140004A7 (es) 2014-05-27
AU2016244246A1 (en) 2016-10-27
EA027821B1 (ru) 2017-09-29
AU2012282316A1 (en) 2013-05-02
SI3255043T1 (sl) 2021-04-30
ZA201401059B (en) 2017-09-27
US9975881B2 (en) 2018-05-22
EP3255043B1 (en) 2021-01-20
AR087168A1 (es) 2014-02-26
CY1124329T1 (el) 2022-07-22
PE20181069A1 (es) 2018-07-04
PL3255043T3 (pl) 2021-07-12
PE20141944A1 (es) 2014-12-24
DK3255043T3 (da) 2021-03-29
HK1245779A1 (zh) 2018-08-31
CN103781781A (zh) 2014-05-07
AU2012282316B2 (en) 2016-07-14
TWI633098B (zh) 2018-08-21
BR112014000636B1 (pt) 2022-08-30
US20130040926A1 (en) 2013-02-14
RS61608B1 (sr) 2021-04-29
JP6006308B2 (ja) 2016-10-12
MX2013015085A (es) 2014-01-24
NZ719176A (en) 2017-11-24
IL230398A (en) 2017-10-31
ES2861927T3 (es) 2021-10-06
CA2841859A1 (en) 2013-01-17
MX342874B (es) 2016-10-17
HUE053703T2 (hu) 2021-07-28
TW201311670A (zh) 2013-03-16
MX353334B (es) 2018-01-09
TW201825479A (zh) 2018-07-16
JP2016190864A (ja) 2016-11-10
CU20160083A7 (es) 2017-03-03

Similar Documents

Publication Publication Date Title
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CL2014001855A1 (es) Compuestos derivados de imidazopirrolidinona o sus sales, formas cristalinas; composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno o enfermedad mediada por la actividad de mdm2 y/o mdm4 tales como enfermedades proliferativas, especialmente cancer.
PE20160874A1 (es) Compuestos quimicos
ECSP23034537A (es) Formulaciones farmaceuticas
PE20150886A1 (es) Compuestos de benceno sustituidos
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CR20140032A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a
DOP2012000105A (es) Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes
MX2014000536A (es) Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
AR083755A1 (es) Formas solidas del acido (s)-2-amino-3-(4-(-2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pirimidin-4-il)fenil)propanoico
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CL2009001112A1 (es) Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
DOP2014000092A (es) N-(3-{[(3-{[2-cloro-5-(metoxi) fenil] amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas
CO6382120A2 (es) Compuestos ciclopropilo
UY35792A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
TH160830A (th) อนุพันธุ์ไพริมิดินิลซัลโฟนาไมด์สำหรับใช้เป็นตัวควบคุมของตัวรับคีโมไคน์
ES2404481R2 (es) Medio de cultivo adecuado para la proliferación de células madre neurales
ECSP12011800A (es) Composición farmacéutica para bajar de peso y procedimiento para obtener la misma
CU20140007A7 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido- pirimidina y su uso como moduladores de receptores de c5a